Direct oral anticoagulant use in special populations

Keyphrases

• Direct Oral Anticoagulants 100%
• Anticoagulant Use 100%
• Special Populations 100%
• Non-valvular Atrial Fibrillation 33%
• Randomized Controlled Trial 33%
• Comorbidity 33%
• Patient Demographics 33%
• Anticoagulants 33%
• Antiphospholipid Antibody Syndrome 33%
• Obesity 16%
• Kidney Disease Progression 16%
• High Risk 16%
• Meta-analysis 16%
• Inclusion Criteria 16%
• Cirrhosis 16%
• National Database 16%
• Cancer Antibodies 16%
• Venous Thromboembolism 16%
• Prospective Randomized Trial 16%
• Informed Consent 16%
• Safety Data 16%
• Gastrointestinal Cancer 16%
• Patient Preference 16%
• Stroke Prevention 16%
• Phase II Trial 16%
• Efficacy Data 16%
• Pharmacokinetic Data 16%
• Advanced Kidney Disease 16%
• Venous Thromboembolism Treatment 16%
• Genitourinary Cancer 16%
• Advanced Cirrhosis 16%
• Triple Positive 16%

Medicine and Dentistry

• Direct Oral Anticoagulant 100%
• Atrial Fibrillation 33%
• Randomized Controlled Trial 33%
• Patient Population 33%
• Liver Cirrhosis 33%
• Venous Thromboembolism 33%
• Antithrombotic 33%
• Antiphospholipid Antibody 33%
• Comorbidity 33%
• Nephropathy 16%
• Chronic Kidney Disease 16%
• Apoplexy 16%
• Meta-Analysis 16%
• Pharmacokinetics 16%
• Gastrointestinal Cancer 16%
• Informed Consent 16%
• Patient Preference 16%
• Urogenital Tract Cancer 16%
• Cancer Antibody 16%
• Phase III Trials 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Direct Oral Anticoagulant 100%
• Anticoagulant Agent 33%
• Atrial Fibrillation 33%
• Randomized Controlled Trial 33%
• Liver Cirrhosis 33%
• Syndrome 33%
• Venous Thromboembolism 33%
• Antiphospholipid Antibody 33%
• Comorbidity 33%
• Kidney Disease 16%
• Chronic Kidney Failure 16%
• Cerebrovascular Accident 16%
• Digestive System Cancer 16%
• Urogenital Tract Cancer 16%
• Cancer Antibody 16%
• Pharmacokinetics 16%
• Phase III Trials 16%
• Preference 16%